News & Updates

The novel neurokinin-1 and -3 receptor antagonist elinzanetant appears to reduce the frequency and severity of vasomotor symptoms (VMS), as well as improve sleep and menopause-related quality of life, as shown in two pivotal phase III trials.

Both symptomatic and asymptomatic hypotension are associated with worse outcomes during treatment with either enalapril or sacubitril/valsartan, but the benefits derived from the combination therapy are maintained or even improved in heart failure (HF) patients with hypotension, a study has shown.